MD3769753T2 - Procedeu de preparare a suspensiilor de nanocristale de propionat de fluticazonă Forma A apoase oftalmice sterile - Google Patents
Procedeu de preparare a suspensiilor de nanocristale de propionat de fluticazonă Forma A apoase oftalmice sterileInfo
- Publication number
- MD3769753T2 MD3769753T2 MDE20210297T MDE20210297T MD3769753T2 MD 3769753 T2 MD3769753 T2 MD 3769753T2 MD E20210297 T MDE20210297 T MD E20210297T MD E20210297 T MDE20210297 T MD E20210297T MD 3769753 T2 MD3769753 T2 MD 3769753T2
- Authority
- MD
- Moldova
- Prior art keywords
- fluticasone propionate
- preparation
- sterile ophthalmic
- ophthalmic aqueous
- sterile
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Invenţia de faţă se referă la un procedeu înbunătăţit de producere a nanosuspensiilor oftalmice apoase topice sterile de nanocristale de propionat de fluticazonă Forma A. Nanosuspensiile oftalmice sterile topice sunt folositoare în tratamentul afecţiunilor inflamatorii ale ochiului cum ar fi blefarita, blefarita posterioară, disfuncţia glandei Meibomiene şi sindromul ochiului uscat prin administrarea topică a nanosuspensiei menţionate pe pleoape, gene sau marginea pleoapelor.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962877599P | 2019-07-23 | 2019-07-23 | |
US201962942551P | 2019-12-02 | 2019-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
MD3769753T2 true MD3769753T2 (ro) | 2022-04-30 |
Family
ID=71738074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20210297T MD3769753T2 (ro) | 2019-07-23 | 2020-07-21 | Procedeu de preparare a suspensiilor de nanocristale de propionat de fluticazonă Forma A apoase oftalmice sterile |
Country Status (21)
Country | Link |
---|---|
US (3) | US11406596B2 (ro) |
EP (1) | EP3769753B1 (ro) |
JP (2) | JP7021301B2 (ro) |
KR (1) | KR20220038443A (ro) |
CN (2) | CN111821261B (ro) |
AU (1) | AU2020317084A1 (ro) |
CA (1) | CA3145055A1 (ro) |
CY (1) | CY1124930T1 (ro) |
DK (1) | DK3769753T3 (ro) |
ES (1) | ES2905793T3 (ro) |
HR (1) | HRP20220165T1 (ro) |
HU (1) | HUE057416T2 (ro) |
LT (1) | LT3769753T (ro) |
MD (1) | MD3769753T2 (ro) |
MX (1) | MX2022000928A (ro) |
PL (1) | PL3769753T3 (ro) |
PT (1) | PT3769753T (ro) |
RS (1) | RS62932B1 (ro) |
SI (1) | SI3769753T1 (ro) |
TW (1) | TW202116326A (ro) |
WO (1) | WO2021014348A1 (ro) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115554238A (zh) * | 2022-10-25 | 2023-01-03 | 苏州欧康维视生物科技有限公司 | 眼用混悬液及其制备方法 |
CN115887372A (zh) * | 2022-10-25 | 2023-04-04 | 苏州欧康维视生物科技有限公司 | 丙酸氟替卡松混悬液及其制备方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0639070B2 (en) * | 1992-05-06 | 2010-09-08 | Alcon Laboratories, Inc. | Use of borate-polyol complexes in ophthalmic compositions |
JP3450805B2 (ja) * | 2000-08-08 | 2003-09-29 | わかもと製薬株式会社 | 水性医薬組成物 |
US6900184B2 (en) * | 2003-04-14 | 2005-05-31 | Wyeth Holdings Corporation | Compositions containing pipercillin and tazobactam useful for injection |
US20060229219A1 (en) * | 2005-04-11 | 2006-10-12 | Advanced Medical Optics, Inc. | Borate-polyol mixtures as a buffering system |
US8010032B2 (en) * | 2005-05-23 | 2011-08-30 | Xerox Corporation | Fuser member comprising deflocculated material |
JP2012528889A (ja) | 2009-06-05 | 2012-11-15 | アーシエックス セラピューティックス, インコーポレイテッド | フルチカゾンの眼科処方物および使用方法 |
TWI489997B (zh) | 2009-06-19 | 2015-07-01 | Alcon Res Ltd | 含有硼酸-多元醇錯合物之水性藥學組成物 |
US20130065888A1 (en) * | 2011-08-15 | 2013-03-14 | Biserka Cetina-Cizmek | Ophthalmic formulations and processes for their preparation |
RU2663117C2 (ru) | 2012-05-08 | 2018-08-01 | Никокс Офтэлмикс, Инк. | Препараты гидрофобных терапевтических средств, способы их получения и применения |
BR112015014262A8 (pt) * | 2012-12-17 | 2019-10-08 | Glaxo Group Ltd | formulação farmacêutica, dispositivo adaptado para distribuição intranasal de uma formulação farmacêutica, e, uso de uma formulação farmacêutica |
TWI773641B (zh) | 2015-05-08 | 2022-08-11 | 日商活效製藥股份有限公司 | 含有糖皮質類固醇(glucocorticoids)之奈米微粒子之水性懸浮液劑 |
-
2020
- 2020-07-21 HU HUE20186965A patent/HUE057416T2/hu unknown
- 2020-07-21 HR HRP20220165TT patent/HRP20220165T1/hr unknown
- 2020-07-21 CA CA3145055A patent/CA3145055A1/en active Pending
- 2020-07-21 US US16/934,807 patent/US11406596B2/en active Active
- 2020-07-21 AU AU2020317084A patent/AU2020317084A1/en active Pending
- 2020-07-21 JP JP2020124238A patent/JP7021301B2/ja active Active
- 2020-07-21 MX MX2022000928A patent/MX2022000928A/es unknown
- 2020-07-21 TW TW109124497A patent/TW202116326A/zh unknown
- 2020-07-21 CN CN202010707466.0A patent/CN111821261B/zh active Active
- 2020-07-21 EP EP20186965.8A patent/EP3769753B1/en active Active
- 2020-07-21 LT LTEP20186965.8T patent/LT3769753T/lt unknown
- 2020-07-21 US US17/629,267 patent/US20220241296A1/en active Pending
- 2020-07-21 CN CN202210807241.1A patent/CN115120557B/zh active Active
- 2020-07-21 PL PL20186965T patent/PL3769753T3/pl unknown
- 2020-07-21 WO PCT/IB2020/056832 patent/WO2021014348A1/en active Application Filing
- 2020-07-21 KR KR1020227006020A patent/KR20220038443A/ko unknown
- 2020-07-21 DK DK20186965.8T patent/DK3769753T3/da active
- 2020-07-21 MD MDE20210297T patent/MD3769753T2/ro unknown
- 2020-07-21 RS RS20220142A patent/RS62932B1/sr unknown
- 2020-07-21 SI SI202030032T patent/SI3769753T1/sl unknown
- 2020-07-21 ES ES20186965T patent/ES2905793T3/es active Active
- 2020-07-21 PT PT201869658T patent/PT3769753T/pt unknown
-
2022
- 2022-01-27 CY CY20221100069T patent/CY1124930T1/el unknown
- 2022-02-03 JP JP2022015508A patent/JP7494230B2/ja active Active
- 2022-06-27 US US17/850,515 patent/US20220323352A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
PT3769753T (pt) | 2022-02-15 |
CN115120557A (zh) | 2022-09-30 |
US20210023001A1 (en) | 2021-01-28 |
HUE057416T2 (hu) | 2022-05-28 |
LT3769753T (lt) | 2022-05-10 |
AU2020317084A1 (en) | 2022-03-03 |
KR20220038443A (ko) | 2022-03-28 |
CN111821261B (zh) | 2022-07-26 |
CA3145055A1 (en) | 2021-01-28 |
JP7494230B2 (ja) | 2024-06-03 |
RS62932B1 (sr) | 2022-03-31 |
EP3769753A1 (en) | 2021-01-27 |
CN115120557B (zh) | 2024-05-07 |
CY1124930T1 (el) | 2023-01-05 |
JP2021017449A (ja) | 2021-02-15 |
JP2022062172A (ja) | 2022-04-19 |
MX2022000928A (es) | 2022-02-22 |
US11406596B2 (en) | 2022-08-09 |
PL3769753T3 (pl) | 2022-04-04 |
WO2021014348A1 (en) | 2021-01-28 |
JP7021301B2 (ja) | 2022-02-16 |
SI3769753T1 (sl) | 2022-04-29 |
DK3769753T3 (da) | 2022-01-31 |
US20220323352A1 (en) | 2022-10-13 |
ES2905793T3 (es) | 2022-04-12 |
EP3769753B1 (en) | 2021-11-17 |
HRP20220165T1 (hr) | 2022-04-29 |
TW202116326A (zh) | 2021-05-01 |
US20220241296A1 (en) | 2022-08-04 |
CN111821261A (zh) | 2020-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3377488T2 (ro) | Compuși heterociclici ca imunomodulatori | |
MD3736270T2 (ro) | Modulatori ai proteinei reglatoare a conductanței transmembranare în fibroza chistică și metode de utilizare | |
WO2020106642A8 (en) | 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin | |
AU2015336400A8 (en) | Novel Aminoalkyl benzothiazepine Derivatives And Uses Thereof | |
MD3769753T2 (ro) | Procedeu de preparare a suspensiilor de nanocristale de propionat de fluticazonă Forma A apoase oftalmice sterile | |
MX2018010292A (es) | Tratamiento de condiciones oculares alergicas con ciclodextrinas. | |
PH12015501942A1 (en) | Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders | |
MX2019001877A (es) | Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas. | |
WO2016098054A9 (en) | Processes for preparing oxathiazin-like compounds | |
WO2014145686A3 (en) | Novel cyclosporin derivatives and uses thereof | |
BR112015023348A2 (pt) | método de inibição ou reversão da progressão da formação de catarata, composição oftálmica, e, método de tratamento de uma doença relacionada ao dobramento de proteínas | |
MX2022003388A (es) | Dispositivos y metodos para la filtracion integrada, secado y procesamiento mecanico de ingredientes farmaceuticos activos. | |
WO2019087130A3 (en) | Method of inhibiting angiogenesis | |
EP3976017A4 (en) | PHARMACOLOGICAL SUBSTANCES FOR THE TREATMENT OF PROTEIN AGGREGATION DISEASES OF THE EYE | |
WO2015048188A8 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
PH12018501019A1 (en) | Diamino pyridine derivatives | |
AU2018240462A1 (en) | Drugs and compositions for the treatment of ocular disorders | |
MX2019011925A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
CR20220006A (es) | Compuestos para tratar enfermedad respiratoria | |
WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
WO2016009225A3 (en) | Method for preventing or treating a protein aggregation disease | |
WO2017106798A3 (en) | Compositions and methods for treating gluten intolerance and disorders arising therefrom | |
EP3643297A4 (en) | OPHTHALMIC COMPOSITION FOR GLUCOMA TREATMENT | |
MX2018004779A (es) | Uso terapeutico de una solucion oftalmica acuosa esteril. | |
EA201501130A1 (ru) | Офтальмологическая фармацевтическая композиция |